Patient characteristics and disease-related variables.
| Parameters | N (%) |
|---|---|
| Age, years, median (range) | 25 (13–60) |
| Gender ratio | M:F=3:1 |
| B-symptoms | 13 (54) |
| Bulky disease | 5 (20.8) |
| Extranodal disease | 5 (20.8) |
| cHL subtypes | |
| Nodular sclerosis | 13 (54) |
| Mixed cellularity | 4 (16.6) |
| Unclassified | 7 (33.3) |
| Previous 2 lines failed | 19 (80) |
| Stage at the time of starting VIBE stage | |
| Stage II | 6 (25) |
| Stage III | 10 (41.6) |
| Stage IV | 8 (33.3) |
| Numbers of VIBE regimen received | |
| Two courses | 9 (37.5) |
| Three courses | 6 (25) |
| Four courses | 9 (37.5) |
Abbreviations: cHL, classical Hodgkin lymphoma; VIBE, vinorelbine, ifosfamide, bendamustine, etoposide.
Blood Res 2021;56:134~140 https://doi.org/10.5045/br.2021.2021039
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd